Jan 07, 2026 5:08pm EST LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
Jan 05, 2026 8:00am EST LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
Dec 01, 2025 8:30am EST LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
Nov 05, 2025 8:00am EST LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Oct 29, 2025 8:00am EDT LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
Sep 30, 2025 8:00am EDT LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
Jul 31, 2025 4:05pm EDT LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
Jul 30, 2025 8:00am EDT LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights